



# 0A01-06 LB. HIV-1 Plasma RNA and Risk of HIV-1 Transmission

## Citation

Lingappa, J. R., J. P. Hughes, D. Donnel, J. M. Baeten, J. I. Mullins, M. S. Campbell, G. E. Gray, et al. 2009. 0A01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission. *Retrovirology* 6(Suppl 3):O12.

## Published Version

doi:10.1186/1742-4690-6-S3-012

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:4569475>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Oral presentation

Open Access

## OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission

JR Lingappa<sup>\*1</sup>, JP Hughes<sup>1</sup>, D Donnel<sup>2</sup>, JM Baeten<sup>1</sup>, JI Mullins<sup>1</sup>,  
MS Campbell<sup>1</sup>, GE Gray<sup>3</sup>, M Essex<sup>4</sup>, C Farquhar<sup>1</sup>, H Rees<sup>3</sup>, A Wald<sup>1</sup>, L Corey<sup>1</sup>  
and C Celum<sup>1</sup>

Address: <sup>1</sup>University of Washington, Seattle, Washington, USA, <sup>2</sup>Fred Hutchinson Cancer Research Centre, Seattle, USA, <sup>3</sup>University of the Witwatersrand, Johannesburg, South Africa and <sup>4</sup>Harvard University, Boston, USA

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

Retrovirology 2009, 6(Suppl 3):O12 doi:10.1186/1742-4690-6-S3-O12

This abstract is available from: <http://www.retrovirology.com/content/6/S3/O12>

© 2009 BioMed Central Ltd.

### Background

Non-sterilizing HIV-1 vaccines may provide public health benefits if they significantly reduce plasma HIV-1 RNA, thus potentially reducing infectiousness. Quantification of reduction in plasma HIV-1 RNA needed to decrease HIV-1 transmission is useful for design of efficacy trials of candidate HIV-1 vaccines. We modeled the relationship between plasma HIV-1 RNA and HIV-1 transmission using data from a prospective study of African heterosexual HIV-1 serodiscordant couples.

### Methods

3408 HIV-1-infected participants with CD4 counts  $\geq 250$  cells/mm<sup>3</sup> enrolled in the Partners in Prevention HSV/HIV Transmission Study and their partners were followed for  $\leq 24$  months. HIV-1 transmission events were assessed for viral genetic linkage within the enrolled partnership by determining HIV-1 env and gag sequences from partners. The relationship between plasma HIV-1 RNA over time and risk of genetically linked HIV-1 transmission was evaluated with a Cox model with a natural cubic spline.

### Results

84 post-enrollment linked HIV-1 transmissions were observed. HIV-1 incidence increased rapidly and non-linearly with higher plasma HIV-1: from 0.53 transmissions per 100 person-years for plasma HIV-1 RNA  $< 10,000$  copies/mL to 6.2 for HIV-1 RNA  $> 1,000,000$  copies/mL ( $p < 0.0001$ ). Baseline HIV-1 RNA in men was, on average,

0.4 log<sub>10</sub> higher than in women; no significant difference in risk of transmission for a given HIV-1 level was observed between men and women ( $p = 0.17$ ). Given the distribution of plasma HIV-1 RNA in this population of stable cohabiting couples, our modeling predicts that a 0.74 log<sub>10</sub> reduction in average plasma HIV-1 RNA in the population would be required for a 50% reduction in HIV-1 transmission risk.

### Conclusion

This analysis provides a detailed description of the relationship between plasma HIV-1 RNA and risk of heterosexual HIV-1 transmission. These findings suggest targets for reduction in HIV-1 RNA for use in evaluating non-sterilizing HIV-1 vaccine candidates in HIV-1 infected persons to reduce risk of heterosexual HIV-1 transmission.